Vascular BioSciences

Received NIH Phase I commercialization award for developing a peptide as a therapeutic adjuvant.

Described preclinical efficacy of inhaled peptide-targeted liposomal formulation for improving hemodynamics and pathology in pulmonary arterial hypertension models.

Introduced a gene expression-driven method to rank combination therapies for pulmonary arterial hypertension using data from arterial biopsy samples.

Showed that peptide-mediated co-administration enhances pulmonary vasodilator selectivity and efficacy in animal models of hypertension.

Demonstrated use of endoarterial biopsy for miRNA and gene expression profiling in pulmonary hypertension, supporting individualized therapy.

Described percutaneous endoarterial biopsy as a method for evaluating vascular histology and gene expression to inform precision therapeutics in pulmonary hypertension.

Reported first orally administered disease-targeting peptide that selectively enhances pulmonary drug efficacy, offering a new approach in targeted therapy.

Article highlighted in The American Journal of Pathology describes a peptide adjuvant that selectively boosts the efficacy of pulmonary vasodilators in pulmonary arterial hypertension.

Presented preclinical results of targeted liposomal therapy and individualized drug ranking for pulmonary arterial hypertension.

Presented research on peptide adjuvants that enhance drug efficacy and gene regulation studies for pulmonary hypertension and sepsis in animal models.

Presented results showing that targeted peptide delivery enhances prostacyclin efficacy in preclinical models of pulmonary hypertension.

Delivered a presentation on disease-selective peptide adjuvants for targeted drug therapy at a leading scientific conference.

Patented technology for devices and procedures enabling minimally invasive collection of vascular tissue samples.